» Articles » PMID: 35634148

Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis

Overview
Journal Front Physiol
Date 2022 May 31
PMID 35634148
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic liver diseases include a broad group of hepatic disorders from different etiologies and with varying degrees of progression and severity. Among them, non-alcoholic fatty (NAFLD) and alcoholic (ALD) liver diseases are the most frequent forms of expression, caused by either metabolic alterations or chronic alcohol consumption. The liver is the main regulator of energy homeostasis and metabolism of potentially toxic compounds in the organism, thus hepatic disorders often promote the release of harmful substances. In this context, there is an existing interconnection between liver and brain, with the well-named brain-liver axis, in which liver pathologies lead to the promotion of neurodegenerative disorders. Alzheimer's (AD) and Parkinson's (PD) diseases are the most relevant neurological disorders worldwide. The present work highlights the relevance of the liver-related promotion of these disorders. Liver-related hyperammonemia has been related to the promotion of perturbations in nervous systems, whereas the production of ketone bodies under certain conditions may protect from developing them. The capacity of the liver of amyloid- (A) clearance is reduced under liver pathologies, contributing to the development of AD. These perturbations are even aggravated by the pro-inflammatory state that often accompanies liver diseases, leading to the named neuroinflammation. The current nourishment habits, named as Western diet (WD) and alterations in the bile acid (BA) profile, whose homeostasis is controlled by the liver, have been also related to both AD and PD, whereas the supplementation with certain compounds, has been demonstrated to alleviate the pathologies.

Citing Articles

Baseline liver fibrosis-4 score correlates to the progression of anxiety and cognitive impairment in patients with Parkinson's disease.

Cheng Y, Chen L, Zhu H, Ge Y, Li L, Guo Y Front Aging Neurosci. 2025; 17:1501319.

PMID: 39925858 PMC: 11802528. DOI: 10.3389/fnagi.2025.1501319.


Redefining Roles: A Paradigm Shift in Tryptophan-Kynurenine Metabolism for Innovative Clinical Applications.

Tanaka M, Szabo A, Vecsei L Int J Mol Sci. 2024; 25(23).

PMID: 39684480 PMC: 11640972. DOI: 10.3390/ijms252312767.


Interactions of Polychlorinated Biphenyls and Their Metabolites with the Brain and Liver Transcriptome of Female Mice.

Bullert A, Wang H, Valenzuela A, Neier K, Wilson R, Badley J ACS Chem Neurosci. 2024; 15(21):3991-4009.

PMID: 39392776 PMC: 11587508. DOI: 10.1021/acschemneuro.4c00367.


Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.

De Col J, de Lima E, Pompeu F, Cressoni Araujo A, de Alvares Goulart R, Bechara M Int J Mol Sci. 2024; 25(7).

PMID: 38612504 PMC: 11011299. DOI: 10.3390/ijms25073694.


The Metabolic Impact of Nonalcoholic Fatty Liver Disease on Cognitive Dysfunction: A Comprehensive Clinical and Pathophysiological Review.

Giuffre M, Merli N, Pugliatti M, Moretti R Int J Mol Sci. 2024; 25(6).

PMID: 38542310 PMC: 10970252. DOI: 10.3390/ijms25063337.


References
1.
Han J, Jo A, Lee S, Bae H, Won Jun D, Cho Y . Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2014; 29(6):1265-72. DOI: 10.1111/jgh.12520. View

2.
Henderson S . Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics. 2008; 5(3):470-80. PMC: 5084248. DOI: 10.1016/j.nurt.2008.05.004. View

3.
Mapstone M, Cheema A, Fiandaca M, Zhong X, Mhyre T, MacArthur L . Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20(4):415-8. PMC: 5360460. DOI: 10.1038/nm.3466. View

4.
Yakhine-Diop S, Morales-Garcia J, Niso-Santano M, Gonzalez-Polo R, Uribe-Carretero E, Martinez-Chacon G . Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease. Aging (Albany NY). 2020; 12(17):16690-16708. PMC: 7521510. DOI: 10.18632/aging.103992. View

5.
Stoeckel L, Arvanitakis Z, Gandy S, Small D, Kahn C, Pascual-Leone A . Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. F1000Res. 2016; 5:353. PMC: 4897751. DOI: 10.12688/f1000research.8300.2. View